Fol. Biol. 2003, 49, 230-234
https://doi.org/10.14712/fb2003049060230
MHC Class I+ and Class I- HPV16-Associated Tumours Expressing the E7 Oncoprotein Do Not Cross-react in Immunization/Challenge Experiments
References
1. , J., Šímová, J., Hájková, R., Sobota, V., Jandlová, T., Šmahel, M., Sobotková E., Vonka, V. (1999) Interleukin 2 gene therapy of residual disease in mice carrying tumours induced by HPV16. Int. J. Oncol. 14, 593-597.
2. , J. (2002a) Animal models for development of therapeutic HPV16 vaccines. Int. J. Oncol. 20, 207-212.
3. , J. (2002b ) Therapeutic vaccines against HPV16associated tumors. Neoplasma 49, 285-289.
4. , J. (2003) Prospects for immunotherapy of MHC class I-deficient tumours. Folia Biol. (Praha) 49, 95-99.
5. , J. (2003) Tumour MHC class I downregulation and immunotherapy. Oncol. Rep. 10, 2005-2008.
6. , L., Thomas, E. K., Hu, S.-L., Hellstrom, I., Hellstrom, K. E. (1991) Human papillomavirus type 16 nucleoprotein E7 is a tumor rejection antigen. Proc. Natl. Acad. Sci. USA 88, 110-114.
<https://doi.org/10.1073/pnas.88.1.110>
7. , M., Bubeník, J., Mikyšková, R., Vonka, V., Šmahel, M., Žák, R., Šímová J., Bieblová, J., Mendoza, L., Jandlová, T. (2002) Tumour-inhibitory and antimetastatic effects of IL-2 in mice carrying MHC class I- tumours of HPV16 origin. Int. J. Oncol. 20, 643-646.
8. , O., Šíma, P., Kunke, D. (2003) Combined suicide gene and immunostimulatory gene therapy using AAV-mediated gene transfer to HPV-16 transformed mouse cell: decrease of oncogenicity and induction of protection. Int. J. Oncol. 22, 569-577.
9. , H., Chang, E. Y., Lin, K.-Y., Kurman, R. J., Pardoll, D. M., Wu, T.-C. (1998) Antigen-specific immunotherapy for murine lung metastastic tumors expressing human papillomavirus type 16 E7 oncoprotein. Int. J. Cancer 78, 41-45.
<https://doi.org/10.1002/(SICI)1097-0215(19980925)78:1<41::AID-IJC8>3.0.CO;2-X>
10. , P., Žák, R., Janoušková, O., Kunke, D., Rittich, S., Dušková, M., Sobotková, E., Marinov, I., Andelová, M., Šmahel, M., Vonka, V. (2003) Immunization with live HPV16-transformed mouse cells expressing the herpes simplex thymidine kinase and either GM-CSF or IL-2. Int. J. Oncol. 23, 775-783.
11. , L. A., Ault, K. A., Wheeler, C. M., Brown, D. R., Barr, E., Alvarez, F. B., Chiacchierini, L. M., Jansen, K. U. (2002) A controlled trial of a human papillomavirus type 16 vaccine. N. Engl. J. Med. 347, 1645-1651.
<https://doi.org/10.1056/NEJMoa020586>
12. , H. I., Lazenby, A., Hayashi, R. J., Pardoll, D. M. (1994) In vivo priming of two distinct antitumor effector populations: the role of MHC class I expression. J. Exp. Med. 179, 1215-1224.
<https://doi.org/10.1084/jem.179.4.1215>
13. , K.-Y., Guarnieri, F. G., Staveley-O'Carroll, K. F., Levitsky, H. I., August, J. T., Pardoll, D. M., Wu, T.-C. (1996) Treatment of established tumors with a novel vaccine that enhances major histocompatibility class II presentation of tumor antigen. Cancer Res. 56, 21-26.
14. , R., Bieblová, J., Šímová, J., Indrová, M., Jandlová, T., Vonka, V., Šmahel, M., Bubeník, J., Mendoza, L. (2003) Local IFN-γ therapy of HPV16-associated tumours. Folia Biol. (Praha) 49, 26-32.
15. , N., Bosch, F. X., de Sanjosé, S., Herrero, R., Castellsagué, X., Shah, K. V., Snijders, P. J. F., Meijer, C. J. L. M. (2003) Epidemiologic classification of human papillomavirus types associated with cervical cancer. N. Engl. J. Med. 348, 518-527.
<https://doi.org/10.1056/NEJMoa021641>
16. , Š., Stránská, R., Šubrtová, J., Kutinová, L., Otáhal, P., Hainz, P., Marešová, L., Šroller, V., Hamšíková, E., Vonka, V. (2002) Immune response to E7 protein of human papillomavirus type 16 anchored on the cell surface. Cancer Immunol. Immunother. 51, 111-119.
<https://doi.org/10.1007/s00262-001-0261-3>
17. , M., Šíma, P., Ludvíková, V., Vonka, V. (2001) Modified HPV 16 E7 genes as DNA vaccine against E7 containing cells. Virology 281, 231-238.
<https://doi.org/10.1006/viro.2000.0794>
18. , M., Šíma, P., Ludvíková, V., Marinov, I., Pokorná, D., Vonka, V. (2003) Immunization with modified HPV 16 E7 genes against oncogenic TC-1 sublines with downregulated expression of MHC class I molecules. Vaccine 21, 1125-1136.
<https://doi.org/10.1016/S0264-410X(02)00519-4>
19. , S. E. (2003) Cervical cancer. Lancet 361, 2217-2225.
<https://doi.org/10.1016/S0140-6736(03)13778-6>
20. , H. (2001) Oncogenic DNA viruses. Oncogene 26, 7820-7823.
<https://doi.org/10.1038/sj.onc.1204958>
21. , S., Mota, S. C. F., Nouta, J., Johnson, M., Lipford, G. B., Offringa, R., van der Burg, S. H., Melief, C. J. M. (2002) Established human papillomavirus type 16-expressing tumors are effectively eradicated following vaccination with long peptides. J. Immunol. 169, 350-358.
<https://doi.org/10.4049/jimmunol.169.1.350>
